Quoin Pharmaceuticals to Announce Corporate Update and Second Quarter 2026 Financial Results on Friday, August 14, 2026

Quoin Pharmaceuticals (NASDAQ: QNRX) plans to issue a corporate update and report its second quarter 2026 financial results for the period ended June 30, 2026, before the U.S. market opens on Friday, August 14, 2026.

Rhea-AI Summary

Quoin Pharmaceuticals (NASDAQ: QNRX) plans to issue a corporate update and report its second quarter 2026 financial results for the period ended June 30, 2026, before the U.S. market opens on Friday, August 14, 2026.

According to Quoin, the announcement will provide an operational update highlighting key achievements during the quarter, recent accomplishments, and financial highlights. The company describes itself as a late clinical-stage specialty pharmaceutical business focused on rare and orphan diseases, with a pipeline built around its QRX003 and QRX009 platform products targeting multiple dermatologic and other rare indications.

Argus Aug 7 session 1 alert

+4.81% close to close 0.2x rel. volume Open Argus

Details

Market reaction after 2Q26 earnings report: QNRX +4.81% in the Aug 7 session

$9.39M Market Cap

In the Aug 7 session, QNRX gained 4.81%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

An active S-3 is listed as ineffective and registers resale securities by selling shareholders. This...

Analysis

An active S-3 is listed as ineffective and registers resale securities by selling shareholders. This scheduled earnings update adds timing information, while the registration does not represent a company offering or company proceeds.

Key Figures

Results period: Second quarter 2026 Quarter end: June 30, 2026 Release date: August 14, 2026 +1 more

Results period

Second quarter 2026

Financial results to be released

Quarter end

June 30, 2026

Second-quarter reporting period

Release date

August 14, 2026

Before the market opens

Platform products

2 products

QRX003 and QRX009

Previous Earnings date Reports

3 past events · Latest: Apr 30

Same Type 3 events

1. Apr 30

   Q1 earnings date

   24h Move

   +9.3%

   Scheduled Q1 2026 results and corporate update before market open

2. Mar 19

   Q4 earnings date

   24h Move

   +5.4%

   Scheduled Q4 and full-year 2025 results and corporate update

3. Oct 30

   Q3 earnings date

   24h Move

   -7.2%

   Scheduled Q3 2025 results and operational update before market open

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

clinical-stage, orphan diseases

2 terms

clinical-stage technical

"a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases"

Clinical-stage describes a drug, therapy, or company whose product is being tested in human trials but has not yet received regulatory approval. For investors, it signals that the project has moved beyond lab work into real-world testing—meaning higher potential reward if trials succeed but also clear risks from trial setbacks, costs, and regulatory delay; think of it like a prototype car on public road tests that could either prove its value or reveal problems that stop it from reaching production.

orphan diseases medical

"focused on rare and orphan diseases"

Orphan diseases are rare medical conditions that affect a small number of patients compared with common illnesses. For investors, they matter because treatments for these conditions often receive special regulatory incentives—like tax credits, faster review, and market exclusivity—so a successful therapy can win a protected, premium-priced niche market much like a specialized product that serves few customers but commands high margins.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

ASHBURN, Va., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the "Company" or "Quoin"), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that it plans to provide a corporate update and release its financial results for the second quarter ended June 30, 2026, before the market opens on Friday, August 14, 2026.

The announcement will include an operational update highlighting key achievements from the quarter, recent accomplishments, and financial highlights from the second quarter of 2026.

About Quoin Pharmaceuticals Ltd.

Quoin Pharmaceuticals Ltd. is a late clinical-stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. We are committed to addressing unmet medical needs for patients, their families, communities and care teams. Quoin's innovative pipeline is focused on two key platform products, QRX003 and QRX009 that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Pachyonychia Congenita, Gorlin Syndrome and Tuberous Sclerosis Complex, Microcystic Lymphatic Malformations, Venous Malformations, Angiofibromas and others. For more information, visit www.quoinpharma.com or LinkedIn for updates.

For further information, contact:

Quoin Pharmaceuticals Ltd.
Dr. Michael Myers, Ph.D., CEO
mmyers@quoinpharma.com

Investor Relations
PCG Advisory
Jeff Ramson
jramson@pcgadvisory.com
(646) 863-6341

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Quoin Pharmaceuticals (NASDAQ: QNRX) report its Q2 2026 financial results?

Quoin Pharmaceuticals plans to report its Q2 2026 financial results on Friday, August 14, 2026, before the market opens. According to Quoin, this release will include a corporate update, operational achievements, recent accomplishments, and financial highlights for the quarter ended June 30, 2026.

What will Quoin Pharmaceuticals include in its August 14, 2026 corporate update for QNRX investors?

The August 14, 2026 corporate update will include operational highlights, key achievements, recent accomplishments, and financial highlights for Q2 2026. According to Quoin, these disclosures will accompany the company’s second quarter 2026 results for the period ended June 30, 2026, released before the market opens.

What is the business focus of Quoin Pharmaceuticals (QNRX) mentioned in the August 7, 2026 announcement?

Quoin Pharmaceuticals is a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases. According to Quoin, its pipeline centers on QRX003 and QRX009, which aim to address multiple dermatologic and other rare indications with significant unmet medical needs in targeted patient populations.

Which rare disease indications are targeted by Quoin Pharmaceuticals’ QRX003 and QRX009 platforms?

QRX003 and QRX009 target several rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, and Pachyonychia Congenita. According to Quoin, they also address Gorlin Syndrome, Tuberous Sclerosis Complex, Microcystic Lymphatic Malformations, Venous Malformations, Angiofibromas and potentially other related conditions.

How can investors get more information about Quoin Pharmaceuticals (QNRX) following its Q2 2026 update?

Investors can find more information on Quoin Pharmaceuticals’ official website at www.quoinpharma.com. According to Quoin, additional updates are available via the company’s LinkedIn page, and investor relations inquiries can be directed to PCG Advisory through the contact details provided in the announcement.

Is Quoin Pharmaceuticals considered a clinical-stage company in its August 7, 2026 QNRX update?

Yes, Quoin Pharmaceuticals describes itself as a late clinical-stage specialty pharmaceutical company. According to Quoin, the company is developing and aiming to commercialize therapeutic products for rare and orphan diseases, supported by its QRX003 and QRX009 platforms targeting multiple specialized indications.